

# Pathogenesis, Detection, and Treatment of Vulnerable Plaque: IVUS, VH, and other IVUS-based Imaging Diagnostics

*Gary S. Mintz, MD*

*Cardiovascular Research Foundation  
New York City, NY*




# Disclosures

- **Boston Scientific**
- **Volcano**
- **Light Lab**
- **Terumo**

# “Vulnerable Plaque” = thrombosis-prone plaque and plaque with a high probability of undergoing rapid progression


## Different Types of Vulnerable Plaque




70% of ACS culprit lesions

30% of ACS culprit lesions

*Naghavi et al. Circulation 2003;108:1664-72*



Proximal 0 —————> 3mm —————> 12mm



EEM CSA = 21.0mm<sup>2</sup>


EEM CSA = 23.5mm<sup>2</sup>

EEM CSA = 13.7mm<sup>2</sup>






# IVUS profile of ruptured plaques: Insights into pre-rupture morphology



	Mean±1SD	CoV	10 <sup>th</sup> Percentile	90 <sup>th</sup> Percentile
Reference				
<b>Lumen CSA</b>	<b>11.7±3.5</b>	<b>0.29</b>	<b>8.1</b>	<b>15.3</b>
EEM CSA	20.2±5.6	0.27	14.2	26.7
P&M CSA	8.5±3.0	0.35	4.9	12.4
Plaque Burden	0.42±0.75	0.18	0.31	0.49
Lesion				
Lumen CSA	4.9±2.7	0.55	2.1	8.6
<b>EEM CSA</b>	<b>20.8±6.0</b>	<b>0.29</b>	<b>14.3</b>	<b>28.5</b>
P&M CSA	15.9±4.9	0.31	9.8	22.4
Min P&M Th	0.5±0.3	0.58	0.2	1.0
<b>Max P&amp;M Th</b>	<b>2.3±0.6</b>	<b>0.25</b>	<b>1.6</b>	<b>3.0</b>
Eccentricity	0.32±0.23	0.71	0.09	0.66
<b>Plaque Burden</b>	<b>0.76±0.10</b>	<b>0.12</b>	<b>0.63</b>	<b>0.88</b>
AS	0.57±0.19	0.34	0.28	0.80
<b>RI</b>	<b>1.10±0.20</b>	<b>0.18</b>	<b>0.87</b>	<b>1.38</b>
Arc of Ca <sup>++</sup>	46.9±51.2	1.09	0	106.7

**99% of ruptured plaques fit 4 of these 5 parameters**



•The 10<sup>th</sup> or 90<sup>th</sup> percentile parameters of the 5 variables with the narrowest coefficient of variance were

- Reference lumen area  $>8.1\text{mm}^2$
- Lesion EEM area  $>14.3\text{mm}^2$
- Lesion max plaque thickness  $>1.6\text{mm}$
- Lesion plaque burden  $>0.63$
- Remodeling index  $>0.87$

Proximal 0 —————> 3mm —————> 12mm

**Unfortunately, it is impossible to determine whether this lesion has the histologic and mechanical substrates for a rupture-prone plaque**

EEM CSA =  $21.0\text{mm}^2$   
Lumen CSA =  $9.5\text{mm}^2$   
P+M CSA =  $11.5\text{mm}^2$

EEM CSA =  $23.5\text{mm}^2$   
Lumen CSA =  $5.5\text{mm}^2$   
P+M CSA =  $18.0\text{mm}^2$   
Max P+M Thickness= $3.0\text{mm}$   
Plaque burden= $0.79$   
Remodeling index= $1.3$


EEM CSA =  $13.7\text{mm}^2$   
Lumen CSA =  $9.3\text{mm}^2$   
P+M CSA =  $4.4\text{mm}^2$



# Virtual Histology™™ IVUS

Only the envelope amplitude (echo intensity) is used in formation of the gray-scale IVUS image

Eight amplitude and frequency parameters are used in Virtual Histology




Frequency of echo signal can also vary, depending on the tissue




# Thin plate spline morphing after which the computer was taught to recognize four basic tissue types


IVUS B scan




Movat pentachrome stain





## Fibroatheroma without evidence of thick fibrous cap



## Fibroatheroma with evidence of thick fibrous cap




# Positive correlation between lipid core and remodeling - negative correlation between fibrous tissue and remodeling



Rodriguez-Granillo, et al. Heart 2006;92:388-391


# Lesion types and remodeling



Rodriguez-Granillo, et al. Heart 2006;92:388-391



# Frequency of TCFA in secondary non-obstructive lesions (<50%DS, n=55)




- 99 TCFA identified
- No relationship between TCFA and gender, diabetes, smoking, hypercholesterolemia, hypertension, family history
- Located within
  - 1<sup>st</sup> 10mm in 35%
  - 10-20mm in 31%
  - 20-30mm in 19%
  - 30-40mm in 14%

On average the proximal 35mm of the artery was imaged

(Rodriguez-Granillo et al. J Am Coll Cardiol 2005;46:2038-42)

# Changes in Plaque Content at Distances from the Ostium of the Coronary artery




Valgimigli et al. *Eur Heart J* 2006 27:655-663

# Diagnostic accuracy of real-time IB (integrated Backscatter)-IVUS


	Sensitivity	Specificity	PPV	NPV
Calcification (n=144)	95%	99%	93%	99%
Fibrosis (n=335)	94%	93%	93%	94%
Lipid pool (n=205)	90%	92%	85%	90%

(Kawasaki et al. *Circulation* 2002;105:2487-92)


## Masson Trichrome Staining







## Conventional IVUS



## Integrated Backscatter Intravascular Ultrasound (IB-IVUS) Color-coded Map





-  *Calcification*
-  *Dense fibrosis*
-  *Fibrosis*
-  *Lipid pool or Intimal Hyperplasia*

(Kawasaki et al. *Circulation* 2002;105:2487-92)





## Stable Plaque





\* guidewire artifact

## Vulnerable Plaque Causing ACS



Lipid pool      Fibrosis      ← Calcification



*(Sano et al. J Am Coll Cardiol in press)*


# Plaque Vulnerability

## Compositional properties


- Large lipid pool
- Thin fibrous cap
- Presence of macrophages

## Mechanical properties






- High strain region



# Principles of Palpography





# 26 vulnerable vs 28 non-vulnerable plaques



*Schaar et al. Circulation 2003;108:2535-41*






***Independent predictors  
of strain were  
macrophages ( $p=0.006$ )  
and smooth muscle  
cells ( $p=0.0001$ )***


*Schaar et al. Circulation 2003;108:2535-41*

# Three-dimensional IVUS images and color mapping of longitudinal stress distribution assessed using finite element analysis




*Imoto et al. J Am Coll Cardiol 2005;46:1507-1515*

# Relationship between stress distribution and plaque shape, luminal stenosis, or vessel remodeling








# Effect of lipid core on stress distribution






# Effect of fibrous cap thickness and surface calcific deposits on stress distribution




Vasa Vasorum  
Interna  
(VVI)




Artery  
Lumen      Wall

Vasa Vasorum  
Externa  
(VVE)




Venous  
Vasa Vasorum  
(VVV)




Vein



# Vasovasorum Imaging



**Normal**





**Hypercholesterolemia**



**Hypercholesterolemia  
+ Statin**




# Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta



Moreno P et al, *Circulation* 2004; 110:2032-8



# Plaque blush, branch location, and calcification were angiographic predictors of progression of mild to moderate coronary stenoses in 68 patients





## Predictors of progression

	OR	p
Plaque blush	12.2	0.0015
Calcification	6.1	0.0235
Branch point	13.9	0.0012



*Casscells et al. Am Heart J 2003;145:813-20*


# Baseline images are acquired for 20 seconds, and regions of interest are assigned



# Contrast is injected, images are acquired for 120 seconds post-injection, and baseline images are subtracted


Range  
of  
enhancement






Pre-injection  
(Frame #200)

Background motions  
are cancelled



Peak Injection  
(Frame #600)

Lumen subtracted  
(microbubble shadow  
effect is not  
calculated)



Post-injection  
(Frame #800)


The enhancement  
lasts for at least 25  
seconds.






# Time-activity curves with quantitative monitoring of plaque perfusion

## Intimo-Medial and Plaque Area



## Adventitia Area



# The PROSPECT Trial

Providing Regional Observations to Study  
Predictors of Events in the Coronary Tree

**Natural history study in pts with ACS**

Multiple imaging techniques

Multiple serum markers

Prolonged follow-up

**Principal sponsor:** Guidant Corporation

**Co-sponsor:** Volcano Therapeutics, 3<sup>rd</sup>



**700 pts with ACS and 1 or 2 vessel CAD  
undergoing PCI will have QCA of entire  
coronary tree, culprit artery imaging (post PCI),  
and both non-culprit arteries also imaged using  
IVUS**

**Virtual histology  
Palpography  
± Thermography (EU only)**

**Meds Rx**  
Aspirin  
Plavix 1yr  
Statin

**F/U: 1 mo, 6 mo, 1 yr  
2 yr, ±3-5 yr  
(event driven)**

**Repeat imaging  
in pts with events**

<i>Naghavi et al. Circulation 2003;108:1664-72</i>	<b>Angiography</b>	<b>IVUS+VH+Stress+VV Imaging</b>
<b>Major criteria</b>		
Active inflammation		+
Thin cap with large lipid core		+
Endothelial denudation		
Fissured plaque		±
Stenosis >90%	+	+
<b>Minor criteria</b>		
Superficial calcified nodule		+
Glistening yellow		
Intraplaque hemorrhage		+
Endothelial dysfunction		
Positive remodeling		+
Three vessel imaging	+	±





# Conclusion

- **Conventional grey scale IVUS cannot detect vulnerable plaques**
- **Other IVUS based imaging modalities have the potential to detect vulnerable plaques, including**
  - **VH+IB IVUS**
  - **Palpography/Stress imaging**
  - **Vasovascularum Imaging**